Tags

Type your tag names separated by a space and hit enter

Proposal for a new nomenclature of disease-modifying antirheumatic drugs.
Ann Rheum Dis. 2014 Jan; 73(1):3-5.AR

Abstract

In light of the recent emergence of new therapeutics for rheumatoid arthritis, such as kinase inhibitors and biosimilars, a new nomenclature for disease-modifying antirheumatic drugs (DMARDs), which are currently often classified as synthetic (or chemical) DMARDs (sDMARDS) and biological DMARDs (bDMARDs), may be needed. We propose to divide the latter into biological original and biosimilar DMARDs (boDMARDs and bsDMARDs, respectively, such as abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab or tocilizumab, but also emerging ones like clazakizumab, ixekizumab, sarilumab, secukinumab or sirukumab) and the former into conventional synthetic and targeted synthetic DMARDs (csDMARDs and tsDMARDs, respectively). tsDMARDs would then constitute only those that were specifically developed to target a particular molecular structure (such as tofacitinib, fostamatinib, baricitinib or apremilast, or agents not focused primarily on rheumatic diseases, such as imatinib or ibrutinib), while csDMARDs would comprise the traditional drugs (such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, gold salts and others). The proposed nomenclature may provide means to group and distinguish the different types of DMARDs in clinical studies and review articles.

Authors+Show Affiliations

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, , Vienna , Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24072562

Citation

Smolen, Josef S., et al. "Proposal for a New Nomenclature of Disease-modifying Antirheumatic Drugs." Annals of the Rheumatic Diseases, vol. 73, no. 1, 2014, pp. 3-5.
Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5.
Smolen, J. S., van der Heijde, D., Machold, K. P., Aletaha, D., & Landewé, R. (2014). Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 73(1), 3-5. https://doi.org/10.1136/annrheumdis-2013-204317
Smolen JS, et al. Proposal for a New Nomenclature of Disease-modifying Antirheumatic Drugs. Ann Rheum Dis. 2014;73(1):3-5. PubMed PMID: 24072562.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Proposal for a new nomenclature of disease-modifying antirheumatic drugs. AU - Smolen,Josef S, AU - van der Heijde,Désirée, AU - Machold,Klaus P, AU - Aletaha,Daniel, AU - Landewé,Robert, Y1 - 2013/09/26/ PY - 2013/9/28/entrez PY - 2013/9/28/pubmed PY - 2014/2/12/medline KW - DMARDs (biologic) KW - DMARDs (synthetic) KW - Outcomes research KW - Rheumatoid Arthritis KW - Treatment SP - 3 EP - 5 JF - Annals of the rheumatic diseases JO - Ann. Rheum. Dis. VL - 73 IS - 1 N2 - In light of the recent emergence of new therapeutics for rheumatoid arthritis, such as kinase inhibitors and biosimilars, a new nomenclature for disease-modifying antirheumatic drugs (DMARDs), which are currently often classified as synthetic (or chemical) DMARDs (sDMARDS) and biological DMARDs (bDMARDs), may be needed. We propose to divide the latter into biological original and biosimilar DMARDs (boDMARDs and bsDMARDs, respectively, such as abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab or tocilizumab, but also emerging ones like clazakizumab, ixekizumab, sarilumab, secukinumab or sirukumab) and the former into conventional synthetic and targeted synthetic DMARDs (csDMARDs and tsDMARDs, respectively). tsDMARDs would then constitute only those that were specifically developed to target a particular molecular structure (such as tofacitinib, fostamatinib, baricitinib or apremilast, or agents not focused primarily on rheumatic diseases, such as imatinib or ibrutinib), while csDMARDs would comprise the traditional drugs (such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, gold salts and others). The proposed nomenclature may provide means to group and distinguish the different types of DMARDs in clinical studies and review articles. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/24072562/Proposal_for_a_new_nomenclature_of_disease_modifying_antirheumatic_drugs_ L2 - https://ard.bmj.com/cgi/pmidlookup?view=long&pmid=24072562 DB - PRIME DP - Unbound Medicine ER -